According to the TCGA Pan-Cancer Atlas data set, 65% of melanomas that have BRAF, NRAS, NF1, or KIT as driver mutation co-occur with mutations in at least one other pathway, most frequently affecting PTEN, Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A), and TP53 (27, 50). This evidence concerns the gene KIT and melanoma.